Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL5809985 | 1.00 | — | — | |
| Water SCHEMBL11750618 | 1.00 | CA2 (0.54) | CA2KDM4ECA5ACA5BCYP3A4 | |
| Water SCHEMBL9333419 | 1.00 | — | — | |
| Water SCHEMBL7032487 | 1.00 | CA2 (0.54) | CA2KDM4ECA5ACA5BCYP3A4 | |
| Water SCHEMBL1120078 | 1.00 | — | — | |
| Water SCHEMBL8140555 | 1.00 | CA2 (0.54) | CA2KDM4ECA5ACA5BCYP3A4 | |
| Water SCHEMBL660657 | 1.00 | — | — | |
| Water SCHEMBL22581621 | 0.95 | — | — | |
| Water SCHEMBL22581609 | 0.95 | — | — | |
| Water SCHEMBL10342957 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4069232-B1 | MASUPIRDINE FOR TREATING BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA | SUVEN LIFE SCIENCES LTD (IN) | 2025-12-24 | — | — | EP | claimed |
| EP-4069231-B1 | COMBINATIONS OF MASUPIRDINE WITH DONEPEZIL OR MEMANTINE FOR TREATING BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH DEMENTIA | SUVEN LIFE SCIENCES LTD (IN) | 2025-07-09 | — | — | EP | claimed |
| CN-114761008-B | Method for treating behavioral and psychological symptoms in patients suffering from dementia | 苏文生命科学有限公司 | 2024-07-19 | — | — | CN | claimed |
| CN-114901282-B | Treatment of behavioral and psychiatric symptoms in dementia patients | 苏文生命科学有限公司 | 2024-06-25 | — | — | CN | claimed |
| US-20240199637-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2024-06-20 | — | — | US | claimed |
| EP-4326276-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | Natco Pharma Ltd (IN) | 2024-02-28 | — | — | EP | claimed |
| CN-117529325-A | Improved process for preparing 7- (morpholinyl) -2- (N-piperazinyl) methylthio [2,3-c ] pyridine derivatives | 纳特科药品有限公司 | 2024-02-06 | — | — | CN | claimed |
| WO-2023057896-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2023-04-13 | — | — | WO | claimed |
| US-20230000859-A1 | METHODS FOR TREATING BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH DEMENTIA | SUVEN LIFE SCIENCES LIMITED (IN) | 2023-01-05 | — | — | US | claimed |
| US-20220409614-A1 | TREATING BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA PATIENTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2022-12-29 | — | — | US | claimed |
| WO-2017199072-A1 | COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS WITH NMDA RECEPTOR ANTAGONIST | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-11-23 | — | — | WO | claimed |
| WO-2017199070-A1 | TRIPLE COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS, ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONIST | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-11-23 | — | — | WO | claimed |
| CN-105814020-A | Process for large scale production of 1- [ (2-bromophenyl) sulfonyl ] -5-methoxy-3- [ (4-methyl-1-piperazinyl) methyl ] -1H-indole disulfonate monohydrate | 苏文生命科学有限公司 | 2016-07-27 | — | — | CN | claimed |
| CN-105452252-A | Polymorph of SYK inhibitors | GILEAD CONNECTICUT INC | 2016-03-30 | — | — | CN | claimed |
| CN-105431137-A | Formulations of SYK inhibitors | GILEAD CONNECTICUT INC | 2016-03-23 | — | — | CN | claimed |
| CN-1636991-A | Sodium-hydrogen exchanger type 1 inhibitor crystals | PFIZER PROD INC (US) | 2005-07-13 | — | — | CN | claimed |
| CN-1384829-A | sodium-hydrogen exchanger type 1 inhibitor crystal | PFIZER PROD INC (US) | 2002-12-11 | — | — | CN | claimed |
| CN-1223261-A | Novel 2-thiocarbpenems | AMERICAN CYANAMID CO (US) | 1999-07-21 | — | — | CN | claimed |
| CN-1104214-A | Novel 2-thiocarbpenems | AMERICAN CRANAMID COMPANY (US) | 1995-06-28 | — | — | CN | claimed |
| CN-1047494-A | 2-amino-1,2,3,4-tetralin compounds that new 8-replaces | ASTRA AB (SE) | 1990-12-05 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000859-A1 | METHODS FOR TREATING BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH DEMENTIA | HTR6, ACHE, HTR5A | CA2 2736/4885KDM4E 600/4885CA5A 2804/4885 |
| US-20220409614-A1 | TREATING BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA PATIENTS | HTR6, CHRNA6, GRM6 | CA2 3073/4885KDM4E 910/4885CA5A 3528/4885 |
| US-20240199637-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NR2C2, NRDC, NDC1 | CA2 3468/4885KDM4E 386/4885CA5A 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.